The longevity industry has become a multi-billion-dollar bet that compounds you’ve never heard of will extend the human lifespan. NMN, NR, fisetin, spermidine, urolithin A — the labels sound like rocket fuel and the price tags read like they are. Behind the marketing sits a smaller, messier reality: most of the human evidence is preliminary, the animal evidence doesn’t translate cleanly, and the smartest researchers in the field will tell you that quietly.
The mouse-to-human translation problem
Most of the headline data on longevity compounds comes from C. elegans worms, fruit flies, and lab mice. These models are useful for screening mechanisms, but they’re poor predictors of human outcomes. Mice live in pathogen-free cages, eat standardized chow, and die predominantly of cancers a 70-year-old human probably won’t develop. A 25 percent lifespan extension in a mouse doesn’t mean 20 extra human years. It often doesn’t mean anything human at all. Resveratrol, the molecule that launched the field two decades ago, looked spectacular in mice and has flunked nearly every well-designed human trial since. The pattern keeps repeating.
What the human trials actually show
The honest accounting on NMN, the most-hyped compound of the moment, is that we have a handful of small human trials lasting weeks to a few months, measuring surrogate markers like NAD+ levels rather than mortality or disease incidence. The same is true for most of the field. None of these studies are powered to tell you whether you’ll live longer or healthier. Rapamycin has the strongest mechanistic case, but it’s a prescription immunosuppressant with real side effects, and the human longevity dosing protocols are extrapolated guesses. The TAME trial on metformin, designed to actually test whether a drug delays age-related diseases, has been trying to fund itself for nearly a decade.
The supplement industry’s clever framing
Companies selling longevity products have learned to describe their compounds with phrases like “supports healthy aging” or “promotes cellular function.” That language is regulatory, not scientific — it lets them advertise without making claims the FDA would force them to substantiate. Meanwhile, their citations point to in vitro studies, animal data, and small early human work, presented as if they amounted to proof. The actual experts running these trials are usually careful in their published papers and looser in podcast appearances and investor decks, which is where most consumers encounter the field.
The takeaway
There may be real longevity drugs in the pipeline. Rapamycin analogs, GLP-1 agonists used for metabolic disease, and a few others have plausible cases worth watching over the next decade. But the products being marketed today are largely sold on extrapolation, not evidence. The boring interventions — sleep, resistance training, not smoking, controlling blood pressure, social connection — have orders of magnitude more data behind them and cost nothing. If you’re spending hundreds a month on capsules to live longer, you’re funding research, not benefiting from it.
Leave a Reply